Ceftriaxone Injection
Ceftriaxone Injection is a cephalosporin antibiotic given by vein (IV) or into a muscle (IM) to treat bacterial infections such as pneumonia, urinary tract infections, skin, bone and joint infections, gonorrhea, and meningitis, and to help prevent infection after certain surgeries.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 36 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Ceftriaxone Injection (Rocephin) is one of the most widely used injectable antibiotics, a cephalosporin that kills bacteria by blocking how they build their cell wall, given into a vein or a muscle for pneumonia, urinary tract infections, bone and joint infections, gonorrhea and meningitis; around since the 1980s, it is available as a generic. Most people tolerate it well, and the usual complaints are soreness or firmness at the injection site, vein irritation with IV doses, and loose stools. Tell your care team about any penicillin or cephalosporin allergy first, and report trouble breathing, swelling, confusion or severe diarrhea right away, even weeks later.
Clinical pearls
- Ceftriaxone does not treat chlamydia, so another medicine may be added when that infection is possible, such as with gonorrhea.
- If your muscle injection was mixed with lidocaine to ease the sting, report bluish skin color right away.
- It must never run through the same IV line at the same time as calcium-containing fluids, which can form solid deposits.
- With chronic liver disease, poor nutrition or low vitamin K stores, expect blood clotting tests during treatment.
Patient information guide A plain-language walkthrough of Ceftriaxone Injection, written from its FDA label.
What Ceftriaxone Injection is used for
▾
Ceftriaxone Injection treats infections caused by susceptible bacteria. The label lists these uses:
- Lower respiratory tract infections
- Acute bacterial otitis media (middle ear infection)
- Skin and skin structure infections
- Urinary tract infections, complicated and uncomplicated
- Uncomplicated gonorrhea
- Pelvic inflammatory disease caused by gonorrhea bacteria
- Bacterial septicemia (bloodstream infection)
- Bone and joint infections
- Intra-abdominal infections
- Meningitis
- Surgical prophylaxis (infection prevention before certain surgeries)
How Ceftriaxone Injection works
▾
Ceftriaxone kills bacteria by blocking the building of their cell walls. Without a sound wall, the bacteria cannot survive. It also works against some bacteria that produce enzymes (beta-lactamases) that destroy other antibiotics.
Ceftriaxone Injection dosage
▾
Ceftriaxone is given by a healthcare professional, either as an IV infusion over about 30 minutes or as an injection deep into a large muscle. It is usually given once a day or split into two doses, and some uses need only one dose. Newborns receive IV doses over a longer time.
- Treatment generally continues for at least 2 days after symptoms resolve.
- Infections caused by Streptococcus pyogenes need at least 10 days of treatment.
- Your prescriber sets the dose and length of treatment.
Dosing details from the FDA-approved label
From the Ceftriaxone Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Pediatric patients: skin and skin structure infections
- Total daily dose 50 to 75 mg/kg given once a day (or in equally divided doses twice a day)
- Maximum: total daily dose should not exceed 2 grams
- Pediatric patients: acute bacterial otitis media
- A single intramuscular dose of 50 mg/kg
- Maximum: not to exceed 1 gram
- Pediatric patients: serious miscellaneous infections other than meningitis
- Total daily dose 50 to 75 mg/kg, given in divided doses every 12 hours
- Maximum: total daily dose should not exceed 2 grams
- Pediatric patients: meningitis
- Initial therapeutic dose 100 mg/kg
- Thereafter, total daily dose of 100 mg/kg/day, may be given once a day (or in equally divided doses every 12 hours)
- Maximum: initial dose not to exceed 4 grams; not to exceed 4 grams daily
- usual duration of therapy is 7 to 14 days
- Adults: usual daily dose
- 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection
- Maximum: total daily dose should not exceed 4 grams
- no dosage adjustment necessary for renal or hepatic impairment; usual duration 4 to 14 days
- Adults: uncomplicated gonococcal infections
- A single intramuscular dose of 250 mg
- Adults: preoperative use (surgical prophylaxis)
- A single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery
- Neonates: intravenous administration
- Intravenous doses should be given over 60 minutes to reduce the risk of bilirubin encephalopathy
- contraindicated in premature neonates and hyperbilirubinemic neonates should not be treated; contraindicated in neonates (≤ 28 days) requiring calcium-containing IV solutions
- Elderly patients
- Dosages recommended for adults require no modification, up to 2 g per day
- Maximum: 2 g per day
- provided there is no severe renal and hepatic impairment
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION Ceftriaxone may be administered intravenously or intramuscularly. Do not use diluents containing calcium, such as Ringer’s solution or Hartmann’s solution, to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see WARNINGS ). There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral). Neonates Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. Ceftriaxone is contraindicated in premature neonates (see CONTRAINDICATIONS ). Ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CONTRAINDICATIONS ). Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy. Pediatric Patients For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams. For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended (see INDICATIONS AND USAGE ). For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Ceftriaxone Injection side effects
▾
Ceftriaxone is generally well tolerated. Common effects include:
Common side effects
- Pain, firmness or tenderness at the injection site
- Phlebitis (vein irritation)
- Diarrhea
- Pain, firmness or tenderness where it is injected
When to get medical help
- Get emergency help for signs of a severe allergic reaction, such as trouble breathing, swelling, or a serious skin reaction.
- Call your doctor if you have confusion, unusual sleepiness, seizures or muscle jerking.
- Tell your doctor if you have diarrhea that is severe or persistent, even weeks or months after treatment.
- Report new anemia symptoms, such as unusual tiredness or paleness, right away.
- Report symptoms of gallbladder or urinary problems, such as pain, little urine or kidney trouble.
- If lidocaine was used in the injection, report bluish skin color or signs of methemoglobinemia right away.
Ceftriaxone Injection warnings and precautions
▾
- Serious allergic reactions (anaphylaxis) can be fatal, and people allergic to penicillin are at higher risk.
- Neurological reactions such as confusion, seizures and muscle jerking have been reported, especially with severe kidney impairment. They resolved after stopping.
- C. difficile diarrhea can range from mild to fatal colitis and can occur even months later.
- Immune-mediated hemolytic anemia has been reported, including fatal cases.
- Ceftriaxone-calcium deposits can form in the gallbladder or urinary tract, most often in children. Staying well hydrated is important.
- Pancreatitis and changes in blood clotting time (prothrombin time) have been reported.
- With lidocaine, methemoglobinemia (a blood oxygen problem) can occur.
Ceftriaxone Injection interactions
▾
The main concerns are mixing problems and calcium.
- Calcium-containing IV solutions: they can form a solid precipitate with ceftriaxone, so they must not be given at the same time.
- Vancomycin, amsacrine, aminoglycosides and fluconazole: they are incompatible in the same mixture, so they are given separately.
- Lidocaine: IV ceftriaxone solutions containing lidocaine are contraindicated.
Interactions listed in the FDA-approved label
From the Ceftriaxone Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Calcium-containing solutions (IV): Precipitation of ceftriaxone-calcium can occur when mixed in the same IV administration line. Must not be administered simultaneously; in patients other than neonates, may be given sequentially if lines are thoroughly flushed between infusions with a compatible fluid. Do not use calcium-containing diluents such as Ringer's or Hartmann's solution to reconstitute.
- Oral calcium-containing products and intramuscular ceftriaxone with calcium products: There have been no reports of an interaction.
- Vancomycin: Incompatible with ceftriaxone in admixtures. Give sequentially with thorough flushing of the IV lines between administrations.
- Amsacrine: Incompatible with ceftriaxone in admixtures. Give sequentially with thorough flushing of the IV lines between administrations.
- Aminoglycosides: Incompatible with ceftriaxone in admixtures. Give sequentially with thorough flushing of the IV lines between administrations.
- Fluconazole: Incompatible with ceftriaxone in admixtures. Give sequentially with thorough flushing of the IV lines between administrations.
- Metronidazole hydrochloride (Flagyl IV): Compatible with ceftriaxone; metronidazole at concentrations greater than 8 mg/mL will precipitate, and the admixture will precipitate if refrigerated. Concentration should not exceed 5 to 7.5 mg/mL metronidazole hydrochloride with ceftriaxone 10 mg/mL; stable 24 hours at room temperature only in 0.9% sodium chloride or D5W; do not refrigerate.
- Other antimicrobial drug solutions: Possible incompatibility if physically mixed or piggybacked. Should not be physically mixed with or piggybacked into solutions containing other antimicrobial drugs.
Read the label’s full interactions text
7 DRUG INTERACTIONS Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible. ( 7.1 ) Calcium-containing products: precipitation can occur. ( 7.2 ) 7.1 Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone in admixtures [see Dosage and Administration (2.3) ]. 7.2 Calcium-containing Products Precipitation of ceftriaxone-calcium can occur when Ceftriaxone for Injection and Dextrose Injection is mixed with calcium-containing solutions in the same IV administration line. Ceftriaxone for Injection and Dextrose Injection must not be administered simultaneously with calcium-containing IV solutions. Ceftriaxone for Injection and Dextrose Injection and calcium-containing solutions may be administered sequentially. [see Warnings and Precautions (5.2) ]
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Ceftriaxone Injection
▾
- Known allergy to ceftriaxone, any cephalosporin, or its ingredients means you should not receive it.
- Penicillin allergy: use with caution.
- Premature newborns, newborns with high bilirubin, and newborns needing calcium IV fluids should not receive it.
- Severe kidney problems, or combined liver and kidney problems, may require dose limits.
- Pregnancy: no clear risk identified in available data.
- Breastfeeding: ceftriaxone is found in breast milk.
- Older adults: kidney function may need monitoring.
Ceftriaxone Injection overdose
▾
Overdose has been reported in people with severe kidney impairment and can cause neurological effects such as encephalopathy, seizures and muscle jerking. The medicine is stopped and supportive treatment is given. Dialysis does not lower the drug level, and there is no specific antidote.
How your body processes Ceftriaxone Injection
▾
After an IM injection, ceftriaxone is completely absorbed, with peak levels in about 2 to 3 hours. In healthy adults its half-life is roughly 6 to 9 hours. About one-third to two-thirds is cleared unchanged in the urine, and the rest passes through bile into stool as inactive compounds. It crosses the placenta and enters the fluid around the brain when the meninges are inflamed.
How to store Ceftriaxone Injection
▾
Store at 20° to 25°C (68° to 77°F). Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Ceftriaxone Injection
44 supplements and herbal products have documented interactions with Ceftriaxone Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 39
- Minor · 2
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Ceftriaxone Injection has been associated with lower levels of 7 nutrients in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
- Higher significance · 6
- Moderate · 1
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Ceftriaxone Injection: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Ceftriaxone Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is ceftriaxone used for?
▾
How will I receive it?
▾
What side effects should I expect?
▾
I’m allergic to penicillin. Can I still get it?
▾
Can it be given with calcium or other IV drugs?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Ceftriaxone Injection available over the counter?
▾
When was Ceftriaxone Injection first available?
▾
Who makes Ceftriaxone Injection?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Ceftriaxone Injection on HelloPharmacist
Ceftriaxone Injection forms and strengths (how it comes)
Ceftriaxone Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Ceftriaxone Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Ceftriaxone and Dextrose in the DUPLEX container is designed to deliver a full 1 g or 2 g dose, so it should not be used in children who need less than the full adult dose.
- Ceftriaxone and Dextrose should be used with caution in people with diabetes or carbohydrate intolerance because it contains dextrose.
- Ceftriaxone and Dextrose must not be given at the same time as calcium-containing IV solutions.
Show 3 more strengths Show fewer strengths
Ceftriaxone Injection on the U.S. market: products, makers and brands
How Ceftriaxone Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
17 companies list 55 Ceftriaxone Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1984. Brand names on the directory include Rocephin, Ceftriaxone And Dextrose; the rest are generics.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Ceftriaxone Injection is used (Medicaid data)
A general measure of how commonly Ceftriaxone Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Ceftriaxone Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Ceftriaxone Injection prescribed? Of the 1,601 medications we measure, Ceftriaxone Injection ranks #191 by Medicaid prescriptions — more than 88% of them.
Utilization by Ceftriaxone Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
ceftriaxone 1000 MG Injection Most dispensed
Summed across the 16 of 45 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1665021
ceftriaxone 500 MG Injection
Summed across the 8 of 38 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1665005
ceftriaxone 2000 MG Injection
Summed across the 12 of 34 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1665046
ceftriaxone 250 MG Injection
Summed across the 7 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 309092
ceftriaxone 100 MG/ML Injectable Solution
Summed across the 6 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 309090
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ceftriaxone Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 49 of 159 listed Ceftriaxone Injection NDCs with Medicaid activity.
Compare Ceftriaxone Injection products
A representative set of FDA-listed product records for Ceftriaxone Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 250 mg | Intramuscular, Intravenous | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Apotex Corp. | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Apotex Corp. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Apotex Corp. | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Apotex Corp. | ANDA | View NDC → |
| 10 g | Intravenous | Apotex Corp. | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Asclemed USA, Inc. | ANDA | View NDC → |
| 1 g/50 mL | Intravenous | B. Braun Medical Inc. | NDA | View NDC → |
| 2 g/50 mL | Intravenous | B. Braun Medical Inc. | NDA | View NDC → |
| 1 g/50 mL | Intravenous | Baxter Healthcare Company | ANDA | View NDC → |
| 2 g/50 mL | Intravenous | Baxter Healthcare Company | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Civica, Inc. | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Civica, Inc. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 10 g | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Hospira, Inc | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Hospira, Inc | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Hospira, Inc | ANDA | View NDC → |
| 1 g | Intravenous | Hospira, Inc | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Hospira, Inc | ANDA | View NDC → |
| 2 g | Intravenous | Hospira, Inc | ANDA | View NDC → |
| 10 g/100 mL | Intravenous | Hospira, Inc | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Proficient Rx LP | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Proficient Rx LP | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Remedyrepack Inc. | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 100 g | Intravenous | Samson Medical Technologies, LLC | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Sandoz Inc | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Sandoz Inc | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Sandoz Inc | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | Sandoz Inc | ANDA | View NDC → |
| 10 g/100 mL | Intravenous | Sandoz Inc | ANDA | View NDC → |
| 250 mg | Intramuscular, Intravenous | Sportpharm LLC | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | Sportpharm LLC × 2 listings | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | Sportpharm LLC × 2 listings | ANDA | View NDC → |
| 500 mg | Intramuscular, Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
| 1 g | Intramuscular, Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
| 2 g | Intramuscular, Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
| 10 g/100 mL | Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
Showing 55 of 55 products — FDA National Drug Code Directory. See every product, package size and price: browse all 55 Ceftriaxone Injection NDCs →
Ceftriaxone Injection side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ceftriaxone Injection — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Ceftriaxone Injection are pyrexia, acute kidney injury, dyspnoea; about 94% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ceftriaxone Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Ceftriaxone Injection FDA approval history
How Ceftriaxone Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Ceftriaxone Injection was first approved by the FDA in 1984 (Brand: ROCEPHIN KIT · Hoffmann La Roche); the first generic version was approved in 1987. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Ceftriaxone Injection recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Ceftriaxone recalls since July 2021.
✅No Ceftriaxone recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2193 2 dose forms · 5 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 376593In current FDA listingsClinical drug / strength (SCD) 100 MG/MLRxCUI 309090 -
Dose form (SCDF) Injection RxCUI 1664992In current FDA listings
Look up RxCUI 2193 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Ceftriaxone Injection supply and shortage status
Whether Ceftriaxone Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Ceftriaxone Injection costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection, Powder, For Solution · Intramuscular; Intravenous | 1 g | $1.44 each | NDC details & price history |
| Injection, Powder, For Solution · Intramuscular, Intravenous | 1 g | $1.44 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Ceftriaxone Injection brand names
Ceftriaxone Injection is sold under 2 brand names in the FDA directory — Rocephin, Ceftriaxone And Dextrose. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Ceftriaxone Injection: manufacturers and labelers
17 companies list Ceftriaxone Injection products with the FDA. By number of product records, the largest are Hospira, Inc, Apotex Corp., Hikma Pharmaceuticals USA Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Ceftriaxone Injection drug class (RxNorm)
Ceftriaxone Injection belongs to the Cephalosporin Antibacterial class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Ceftriaxone Injection page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. B. Braun Medical Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →